TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01453686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1%
Description: Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate 0.05%
Description: Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
Study: NCT02772835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medin-cno
Description: Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medin-cno
Description: Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
Study: NCT03905525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Biological

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Biological

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Biological

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Biological

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Biological

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Biological

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid placebo for injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid placebo for injections
Study: NCT01153347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT00596336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Description: Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: trispecific influenza vaccine 0.5 ml subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: trispecific influenza vaccine 0.5 ml subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: trispecific influenza vaccine 0.5 ml subcutaneously
Study: NCT00768846

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V Stent
Description: Everolimus-eluting Xience V Stent
Study: NCT01958580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04296188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus anterior plane block
Description: ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
Study: NCT04544982

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blue fenugreek kale extract
Description: One capsule to be taken orally before breakfast and one capsule after lunch, with water.
Study: NCT01099748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone 50 - 150 mg QD (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine + Methadone
Description: Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
Study: NCT02019615

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
Study: NCT00241410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OralvacB2MPL
Description: Comparison of different dosages of drug
Study: NCT01153347

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT04544982

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule to be taken orally before breakfast and one capsule after lunch, with water.
Study: NCT02834494

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3D Shear Wave Elastography (SWE)
Description: Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
Study: NCT00241410

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OralvacB2MPL
Description: Comparison of different dosages of drug
Study: NCT01127074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KS24.22 cells
Description: The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites.
Study: NCT03906123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBP
Description: NBP soft capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Soft capsules manufactured to mimic NBP
Study: NCT00602225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study: NCT02835820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: 12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
Study: NCT03471650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
Study: NCT03992716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven® extra Nitrogen
Description: SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olimel N9E
Description: Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
Study: NCT03554746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GC group
Description: 1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps~3. Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~   1. clam ex. without resistance~  2. single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~   <!-- -->~   1. maintain 3rd to 4th ex.~  2. single leg standing on rock board to maintain balance 6th:~   <!-- -->~   1. maintain 5th ex.~  2. lunge ex. without hip internal rotation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CG group
Description: 1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps
Study: NCT03982784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection TQLB(transmuscular quadratus lumborum block)
Description: Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
Study: NCT01396148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate dose escalation
Description: sunitinib starting dose will be 15mg/m\^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib 50mg daily on Schedule 4/2
Study: NCT03910842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-TriCAR-T/SILK
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
Study: NCT02834494

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biopsy
Description: Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
Study: NCT02090218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel
Description: I-Gel supraglottic airway device
Study: NCT03982784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine given as IPCA(intravenous patient controlled analgesia)
Description: PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine given as IPCA(intravenous patient controlled analgesia)
Description: PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
Study: NCT02258568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking abstinence counseling
Description: Telephone smoking abstinence counseling based on motivational interviewing concepts
Study: NCT01536028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study: NCT02090218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LTS, ETI or current airway management practice
Description: Laryngeal tube, endotracheal tube, bag-mask-ventilation
Study: NCT04347902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lipid Emulsion
Description: Various types of intravenous lipids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lipid Emulsion
Description: Various types of intravenous lipids
Study: NCT01536028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
Study: NCT04347902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Lipid Emulsion
Description: Various types of intravenous lipids
Study: NCT01121237

Intervention type: DRUG
Intervention: Recombinant human erythropoietin alfa (biosimilar)
Description: Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
Study: NCT03214965

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook group
Description: A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
Study: NCT04631198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal rebalancing
Description: the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
Study: NCT03950115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Description: IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
Study: NCT03398174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise
Description: Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise
Description: Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home.
Study: NCT03714217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telenutrition Counseling
Description: A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
Study: NCT02941978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
Study: NCT03052725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reslizumab
Description: Reslizumab was provided in a pre-filled syringe.
Study: NCT03398174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home.
Study: NCT02148601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antibiotic Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin (before randomization)
Description: Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (before randomization)
Description: Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
Study: NCT03143894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.